柳药集团：SIF001目前已进入美国一期临床试验

Core Viewpoint - Liu Pharmaceutical Group (603368) is actively involved in the research of SIF001, an innovative monoclonal antibody drug targeting key factors in inflammatory responses, representing the first drug addressing the "inflammatory cause" of epilepsy globally, particularly beneficial for patients resistant to traditional medications [1] Group 1 - The SIF001 drug is designed to fill the treatment mechanism gap for drug-resistant epilepsy [1] - The project has entered Phase I clinical trials in the United States, which commenced in June this year, aiming to recruit 72 participants and expected to complete by early 2026 [1] - In China, the IIT trial is being conducted at Xuanwu Hospital of Capital Medical University, scheduled from August 2024 to July 2026, with progress reported to be smooth [1] Group 2 - Data from the related trials is anticipated to be presented at the upcoming epilepsy conference in the United States by the end of this year [1]